{"id":569844,"date":"2021-10-20T10:32:03","date_gmt":"2021-10-20T10:32:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=569844"},"modified":"2021-10-20T10:32:03","modified_gmt":"2021-10-20T10:32:03","slug":"lichen-planus-therapeutic-pipeline-assessment-clinical-nonclinical-studies-and-emerging-therapies-key-companies-afyx-therapeutics-novartis-actellion-kiniksa-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lichen-planus-therapeutic-pipeline-assessment-clinical-nonclinical-studies-and-emerging-therapies-key-companies-afyx-therapeutics-novartis-actellion-kiniksa-and-others_569844.html","title":{"rendered":"Lichen Planus Therapeutic Pipeline Assessment, Clinical &#038; Non-Clinical Studies and Emerging Therapies | Key Companies- AFYX Therapeutics, Novartis, Actellion, Kiniksa, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Lichen Planus Therapeutic Pipeline Assessment, Clinical &amp; Non-Clinical Studies and Emerging Therapies | Key Companies- AFYX Therapeutics, Novartis, Actellion, Kiniksa, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Lichen Planus Therapeutic Pipeline Assessment, Clinical &amp; Non-Clinical Studies and Emerging Therapies | Key Companies- AFYX Therapeutics, Novartis, Actellion, Kiniksa, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Lichen Planus Pipeline Insight, 2021&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Lichen Planus Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The<strong> Lichen Planus Pipeline report<\/strong> embraces in-depth commercial and clinical assessment of the Lichen Planus pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, <strong>Lichen Planus collaborations<\/strong>, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Lichen Planus Therapeutics Landscape\" src=\"https:\/\/www.abnewswire.com\/uploads\/8d8ccd5d7862b8079901b9f74cfe9e6d.jpg\" alt=\"Lichen Planus Therapeutics Landscape\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Lichen Planus Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Lichen Planus<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Lichen Planus Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Lichen Planus key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lichen Planus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Lichen Planus market.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Lichen Planus Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The dynamics of the Lichen Planus market is anticipated to change in the coming years owing to the improvement in the research and development activities so that the market will comprise efficient treatment options. The launch of emerging therapies is expected during the forecast period.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key companies in the Lichen Planus market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">AFYX Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Novartis<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Actellion<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Kiniksa Pharmaceuticals<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Lichen Planus Therapies covered in the report includes:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rivelin-clobetasoL<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AIN457 (Cosentyx)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Valchlor (mechlorethamine)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">KPL-716<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample Pages @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lichen-planus-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Lichen Planus Emerging Therapies and Key Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Report Highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">A better understanding of disease pathogenesis contributing to the development of <strong>novel therapeutics for Lichen Planus<\/strong>.&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In the coming years, the Lichen Planus market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The companies and academics are working to assess challenges and seek opportunities that could influence <strong>Lichen Planus Research &amp; Development<\/strong>. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">A detailed portfolio of major pharma players who are involved in fueling the Lichen Planus treatment market. Several potential therapies for Lichen Planus are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Lichen Planus market size in the coming years.&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Our in-depth analysis of the <strong>Lichen Planus pipeline assets<\/strong> (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Download Sample Pages @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/lichen-planus-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Lichen Planus Pipeline Landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Lichen Planus&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Lichen Planus Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Lichen Planus &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Lichen Planus Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Lichen Planus Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Lichen Planus Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Lichen Planus Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Lichen Planus Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Lichen Planus Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Lichen Planus Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Lichen Planus Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Lichen Planus Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Visit to get the sample report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/lichen-planus-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/lichen-planus-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Latest Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/global-kinase-inhibitor-in-autoimmune-diseases-market\">Global Kinase Inhibitor in Autoimmune Diseases Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &#8220;Global Kinase Inhibitor in Autoimmune Diseases&nbsp; Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the Global Kinase Inhibitor in Autoimmune Diseases market size, shares, and trends analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Trending Healthcare Blog&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Nutraceutical Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The global demand for Nutraceuticals as a nutritional product for good health &amp; well-being and as a medicine has grown significantly over the past two to three decades. As per DelveInsight, the Nutraceuticals Market is expected to grow at a CAGR of 8.82% by 2026, owing to the rising demand and proactive participation by global companies in the segment. The key companies dominating the global Nutraceutical Market include Koninklijke, Fonterra, DuPont, Nemours, Ingredion Incorporated, ADM, Tate &amp; Lyle, Cargill, and several others.&nbsp;<strong>Read More: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/blog\/nutraceuticals-market?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Companies in Nutraceutical Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=lichen-planus-therapeutic-pipeline-assessment-clinical-nonclinical-studies-and-emerging-therapies-key-companies-afyx-therapeutics-novartis-actellion-kiniksa-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=lichen-planus-therapeutic-pipeline-assessment-clinical-nonclinical-studies-and-emerging-therapies-key-companies-afyx-therapeutics-novartis-actellion-kiniksa-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP Lichen Planus Pipeline Insight, 2021&#8243; report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Lichen Planus Market. The Lichen Planus Pipeline report embraces in-depth commercial and clinical assessment of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/lichen-planus-therapeutic-pipeline-assessment-clinical-nonclinical-studies-and-emerging-therapies-key-companies-afyx-therapeutics-novartis-actellion-kiniksa-and-others_569844.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-569844","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/569844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=569844"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/569844\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=569844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=569844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=569844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}